Medicure Stock Price, News & Analysis

Medicure Inc. (OTC: MCUJF) announced the grant of stock options to certain officers, allowing the purchase of 90,000 common shares at $1.10 each. The options, which vest immediately, can be exercised over five years and require TSX Venture Exchange approval. Medicure is focused on the U.S. cardiovascular market and markets AGGRASTAT® and ZYPITAMAG®. The company's operations include Marley Drug, a North Carolina pharmacy providing an Extended Supply mail order program across many states.

Medicure Inc. (TSXV: MPH, OTC: MCUJF) announced the appointment of David Gurvey as Chief Financial Officer, effective June 28, 2021. Gurvey, a seasoned finance leader, previously served as CFO at DiaMedica Therapeutics, where he played a crucial role in enhancing company value from $2.4 million to $40 million. The Board expressed confidence in Gurvey's ability to translate strategic vision into operational success, aiming to bolster Medicure's growth in the U.S. cardiovascular market, particularly through its key products AGGRASTAT® and ZYPITAMAG®.

Medicure reported its Q1 2021 results, showing net revenue of $4.9 million, up from $3.0 million in Q1 2020. The sales from AGGRASTAT® were $2.6 million, slightly down from $2.7 million year-over-year. Significant contributions came from Marley Drug, generating $2.1 million in revenue, alongside ZYPITAMAG® with $161,000. Adjusted EBITDA improved to $31,000 compared to a loss of $1.3 million in the previous year. The net loss reduced to $1.0 million or $0.10 per share from $1.5 million or $0.14 per share in Q1 2020.

Medicure Inc. (OTC: MCUJF) will release its financial results for Q1 2021 on May 10, 2021. A conference call is scheduled for May 11 at 7:30 AM CT to discuss the 2020 annual and Q1 results. The company focuses on pharmaceuticals for the U.S. cardiovascular market and markets AGGRASTAT® and ZYPITAMAG® through its subsidiary Medicure Pharma Inc. Additionally, it operates Marley Drug, a pharmacy offering an Extended Supply mail order program, enhancing healthcare access while aiming to lower costs for consumers.

Medicure Inc. (OTC: MCUJF) announced the resignation of Chief Financial Officer James Kinley, effective May 15, 2021, after nearly a decade of service. Kinley is leaving to pursue another opportunity. The company is actively searching for a new CFO and has appointed Dr. Neil Owens, the current COO, as interim CFO. CEO Albert D. Friesen expressed gratitude for Kinley's contributions. Medicure focuses on the development of cardiovascular therapies, particularly AGGRASTAT® and ZYPITAMAG®, and operates Marley Drug, a pharmacy offering extended supply programs.

Medicure reported a net revenue of $11.6 million for the year ended December 31, 2020, down from $20.2 million in 2019. Quarterly revenue also decreased to $2.4 million from $3.5 million. AGGRASTAT® sales dropped to $10.6 million due to reduced volumes from COVID-19 impacts. Conversely, ZYPITAMAG® and Marley Drug contributed $453,000 and $340,000 respectively. The adjusted EBITDA was negative $3.9 million, in line with 2019. The net loss for 2020 was $6.8 million, a significant reduction from $19.8 million in 2019. Unrestricted cash fell to $2.7 million from $13.0 million.

Medicure Inc. will participate in Renmark Financial Communications' live Virtual Non-Deal Roadshow on March 30, 2021, at 1:00 PM EST. This event aims to present the latest investor insights and will feature Dr. Albert Friesen, CEO and Chairman. Stakeholders and investors are invited to register for the live session, which will also include a Q&A segment. Limited registration is available, but a replay will be accessible on Medicure's website afterward. Medicure focuses on cardiovascular therapies in the U.S.

Medicure Inc. (OTC: MCUJF) announced participation in Renmark Financial Communications' Virtual Non-Deal Roadshow on March 9, 2021, at 12:00 PM EST. The event aims to present the latest investor insights featuring CEO Dr. Albert Friesen, followed by a live Q&A. Stakeholders and investors are invited to register for the event, with access to a replay available on the company’s website. Medicure focuses on therapies in the U.S. cardiovascular market, including AGGRASTAT® and ZYPITAMAG®.

Medicure Inc. (TSXV: MPH, OTC: MCUJF) announced its participation in Renmark Financial Communications' Virtual Non-Deal Roadshow on February 23, 2021, at 12:00 PM EST. CEO Albert Friesen will present the latest investor insights and engage in a Q&A session. Stakeholders are encouraged to register for this live event, which may have limited capacity, although a replay will be available on the company’s website. Medicure specializes in cardiovascular therapies, including AGGRASTAT® and ZYPITAMAG® in the U.S., and runs Marley Drug, a pharmacy providing a mail-order drug program.